Synthesis and Preclinical Evaluation of a
18F-BMS-986192
68Ga-BMS-986192
68Ga-adnectin
PD-1/PD-L1 checkpoint inhibitors
PD-L1 PET imaging
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
12
10
2020
accepted:
03
01
2021
pubmed:
1
2
2021
medline:
7
1
2022
entrez:
31
1
2021
Statut:
ppublish
Résumé
Blocking the interaction of the immune checkpoint molecule programmed cell death protein-1 and its ligand, PD-L1, using specific antibodies has been a major breakthrough for immune oncology. Whole-body PD-L1 expression PET imaging may potentially allow for a better prediction of response to programmed cell death protein-1-targeted therapies. Imaging of PD-L1 expression is feasible by PET with the adnectin protein
Identifiants
pubmed: 33517324
pii: jnumed.120.258384
doi: 10.2967/jnumed.120.258384
pmc: PMC8882891
doi:
Substances chimiques
B7-H1 Antigen
0
BMS-986192
0
CD274 protein, human
0
Peptide Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1234Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Theranostics. 2018 Nov 28;8(21):6070-6087
pubmed: 30613283
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Nucl Med. 2020 Oct;61(10):1455-1460
pubmed: 32060213
Bioconjug Chem. 2018 Jan 17;29(1):96-103
pubmed: 29125731
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Oncoimmunology. 2018 Mar 6;7(7):e1438111
pubmed: 29900038
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Cancer Res. 2015 Jul 15;75(14):2928-36
pubmed: 25977331
Clin Cancer Res. 2004 Aug 1;10(15):5094-100
pubmed: 15297412
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Cells. 2019 Aug 01;8(8):
pubmed: 31374957
J Nucl Med. 2018 Mar;59(3):529-535
pubmed: 29025984
Onco Targets Ther. 2018 Sep 19;11:5973-5989
pubmed: 30275703
Cancer. 2010 Apr 1;116(7):1757-66
pubmed: 20143437
EJNMMI Res. 2018 Apr 12;8(1):30
pubmed: 29651565
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Crit Rev Oncol Hematol. 2016 May;101:75-85
pubmed: 26969107
Protein Eng Des Sel. 2011 Jan;24(1-2):3-9
pubmed: 21068165
Pigment Cell Melanoma Res. 2015 May;28(3):245-53
pubmed: 25477049
Transl Lung Cancer Res. 2015 Dec;4(6):743-51
pubmed: 26798583
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Melanoma Manag. 2017 Dec;4(4):175-178
pubmed: 30190923
Ther Adv Urol. 2015 Dec;7(6):365-77
pubmed: 26622321
Cancer J. 2018 Jan/Feb;24(1):41-46
pubmed: 29360727
Front Immunol. 2019 Jun 28;10:1485
pubmed: 31316521
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9
pubmed: 15569934
Theranostics. 2018 Jun 7;8(13):3559-3570
pubmed: 30026866
Am J Transplant. 2012 Oct;12(10):2575-87
pubmed: 22900886
J Nucl Med. 2015 Aug;56(8):1169-76
pubmed: 26089548
J Exp Med. 2016 Dec 12;213(13):2835-2840
pubmed: 27903604